Mannkind (MNKD) Amortization of Deferred Charges (2015 - 2026)
Mannkind (MNKD) reported Amortization of Deferred Charges of $452000.0 for Q1 2026, up 314.68% year-over-year from $109000.0 in Q1 2025, and up 67.41% on a QoQ basis from $270000.0 in Q4 2025.
Mannkind (MNKD) has 9 years of Amortization of Deferred Charges data on file, last reported at $452000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges rose 314.68% year-over-year to $452000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $885000.0 (down 22.91% YoY) and the FY2025 annual result came in at $646000.0, down 60.75% from the prior year.
- Amortization of Deferred Charges grew to $452000.0 in Q1 2026 per MNKD's latest filing, from $270000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $469000.0 in Q1 2022 and bottomed at -$114000.0 in Q4 2022.
- The 5-year median for Amortization of Deferred Charges is $363000.0 (2022), against an average of $296235.3.
- The widest annual swing landed in 2023, when Amortization of Deferred Charges jumped 419.3%; it then slumped 84.3% in 2025.
- Tracing MNKD's Amortization of Deferred Charges over 5 years: stood at -$114000.0 in 2022, then jumped by 419.3% to $364000.0 in 2023, then declined by 14.01% to $313000.0 in 2024, then retreated by 13.74% to $270000.0 in 2025, then jumped by 67.41% to $452000.0 in 2026.
- Per Business Quant, the three latest MNKD Amortization of Deferred Charges figures stand at $452000.0 (Q1 2026), $270000.0 (Q4 2025), and $106000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 452,000.00 |
| Mar 31, 2026 | 452,000.00 |
| Dec 31, 2025 | 270,000.00 |
| Dec 31, 2025 | 270,000.00 |
| Sep 30, 2025 | 106,000.00 |
| Sep 30, 2025 | 106,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Dec 31, 2024 | 313,000.00 |
| Dec 31, 2024 | 313,000.00 |
| Sep 30, 2024 | 363,000.00 |
| Sep 30, 2024 | 363,000.00 |
| Jun 30, 2024 | 363,000.00 |
| Jun 30, 2024 | 363,000.00 |
| Mar 31, 2024 | 363,000.00 |
| Mar 31, 2024 | 363,000.00 |
| Dec 31, 2023 | 364,000.00 |
| Dec 31, 2023 | 364,000.00 |
| Sep 30, 2023 | 363,000.00 |
| Sep 30, 2023 | 363,000.00 |
| Jun 30, 2023 | 363,000.00 |
| Jun 30, 2023 | 363,000.00 |
| Mar 31, 2023 | 469,000.00 |
| Mar 31, 2023 | 469,000.00 |
| Dec 31, 2022 | -114,000.00 |
| Dec 31, 2022 | -114,000.00 |
| Sep 30, 2022 | 363,000.00 |
| Sep 30, 2022 | 363,000.00 |
| Jun 30, 2022 | 363,000.00 |
| Jun 30, 2022 | 363,000.00 |
| Mar 31, 2022 | 469,000.00 |
| Mar 31, 2022 | 469,000.00 |
| Dec 31, 2020 | 298,000.00 |
| Dec 31, 2020 | 298,000.00 |
| Sep 30, 2020 | 303,000.00 |
| Sep 30, 2020 | 303,000.00 |
| Jun 30, 2020 | 294,000.00 |
| Jun 30, 2020 | 294,000.00 |
| Mar 31, 2020 | 282,000.00 |
| Mar 31, 2020 | 282,000.00 |
| Dec 31, 2019 | 279,000.00 |
| Dec 31, 2019 | 279,000.00 |
| Sep 30, 2019 | 285,000.00 |
| Sep 30, 2019 | 285,000.00 |
| Jun 30, 2019 | 223,000.00 |
| Jun 30, 2019 | 223,000.00 |
| Mar 31, 2019 | 395,000.00 |
| Mar 31, 2019 | 395,000.00 |
| Dec 31, 2016 | 353,000.00 |
| Dec 31, 2016 | 353,000.00 |
| Sep 30, 2016 | 5.80 Mn |
| Sep 30, 2016 | 5.80 Mn |
| Jun 30, 2016 | 1.44 Mn |
| Jun 30, 2016 | 1.44 Mn |
| Mar 31, 2016 | 1.17 Mn |
| Mar 31, 2016 | 1.17 Mn |
| Dec 31, 2015 | 854,000.00 |
| Dec 31, 2015 | 854,000.00 |
| Sep 30, 2015 | 533,000.00 |
| Sep 30, 2015 | 533,000.00 |
| Jun 30, 2015 | 232,000.00 |
| Jun 30, 2015 | 232,000.00 |
| Mar 31, 2015 | 33,000.00 |
| Mar 31, 2015 | 33,000.00 |